Prosecution Insights
Last updated: November 12, 2026
Application No. 18/756,527

Novel Peptide Compound Or Pharmaceutically Acceptable Salt Thereof

Non-Final OA §102§103§DOUBLEPATENT
Filed
Jun 27, 2024
Priority
May 21, 2019 — RE 10-2019-0059628 +2 more
Examiner
SABILA, MERCY HELLEN
Art Unit
1654
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Eyebio Korea
OA Round
1 (Non-Final)
57%
Grant Probability
Moderate
1-2
OA Rounds
99%
With Interview

Examiner Intelligence

Grants 57% of resolved cases
57%
Career Allowance Rate
159 granted / 278 resolved
-2.8% vs TC avg
Strong +46% interview lift
Without
With
+46.4%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
54 currently pending
Career history
337
Total Applications
across all art units

Office Action

§102 §103 §DOUBLEPATENT
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Priority This application is a CON of 17/613,176 11/22/2021 now Patent 12428446. 17/613,176 was filed on and is a U.S. national Stage application under 35 U.S.C. 371 of International Patent Application No. PCT/KR2020/006594 filed 05/20/2020, which claims the benefit of the priority of Korean Patent Application No. 10-2019-0059628 filed 05/21/2019. Receipt is acknowledged of certified copies of papers required by 37 CFR 1.55. Information Disclosure Statement The information disclosure statements submitted on 06/27/2024 has been considered by the examiner. Claim Status Claims 1-16 are being examined on the merits in this office action. Claim Objections Claims 3, 5, 9, and 14 are objected to because of the following informalities: It is noted that claims 3, 5, 9, and 14 recites amino acid sequences that do not have SEQ ID numbers. Applicants are required to amend the claims to recite SEQ ID NOS. for each of the amino acid sequences contained therein. If the corresponding sequences are not present in the sequence listing filed on 06/27/2024, Applicants are requested to submit an updated sequence listing containing all the sequences disclosed in the instant application, as appropriate. 37 CFR 1.831(c) requires that each nucleotide and/or amino acid sequence set forth in a "Sequence Listing XML" in accordance with 37 CFR § 1.831(a) must be referenced by a sequence identifier as defined in 37 CFR 1.832(a) (see MPEP § 2412.05(a)), preceded by the notation "SEQ ID NO:" or the like, when the sequence appears in the description or claims (See MPEP 2412.04). Items 1) and 2) provide general guidance related to requirements for sequence disclosures. 37 CFR 1.821(c) requires that patent applications which contain disclosures of nucleotide and/or amino acid sequences that fall within the definitions of 37 CFR 1.821(a) must contain a "Sequence Listing," as a separate part of the disclosure, which presents the nucleotide and/or amino acid sequences and associated information using the symbols and format in accordance with the requirements of 37 CFR 1.821 - 1.825. This "Sequence Listing" part of the disclosure may be submitted: via EFS-Web (see Section I.1 of the Legal Framework for EFS-Web (https://www.uspto.gov/patents-application-process/filing-online/legal-framework-efs-web), hereinafter "Legal Framework") as an ASCII text file, together with an incorporation-by-reference of the material in the ASCII text file in a separate paragraph of the specification identifying: the name of the ASCII text file; the date of creation; and the size of the ASCII text file in bytes; on compact disc(s) in duplicate according to 37 CFR 1.52(e)(1)(ii) and (4), labeled according to 37 CFR 1.52(e)(6), together with a statement that the duplicate compact discs are identical and an incorporation-by-reference of the material in the ASCII text file according to 37 CFR 1.52(e)(5) in a separate paragraph of the specification identifying: the name of the ASCII text file; the date of creation; and the size of the ASCII text file in bytes; via EFS-Web as a PDF (not recommended); or on paper. 37 CFR 1.821(e) requires that a copy of the "Sequence Listing" must also be submitted in computer readable form (CRF) in accordance with the requirements of 37 CFR 1.824. If a "Sequence Listing" ASCII text file submitted via EFS-Web on the application filing date complies with the requirements of 37 CFR 1.824(a)(2) - (6) and (b), and applicant has not filed a "Sequence Listing" as a PDF, the text file will serve as both the "Sequence Listing" required by 37 CFR 1.821(c) and the CRF required by 37 CFR 1.821(e), and the statement of identity under the "Legal Framework" is not required. If the "Sequence Listing" required by 37 CFR 1.821(c) is filed via EFS-Web as a PDF, then the "Legal Framework" requires submission of a statement that the "Sequence Listing" content of the PDF copy and the ASCII text file copy submitted via EFS-Web are identical. If the "Sequence Listing" required by 37 CFR 1.821(c) is filed on paper or compact disc, then 37 CFR 1.821(f) requires submission of a statement that the "Sequence Listing" content of the paper or compact disc copy and the CRF are identical. Applicants are advised to amend claims 3, 5, 9, and 14 to recite a SEQ ID NO. for the amino acid sequences contained therein. If the corresponding sequences are not present in the sequence listing filed on 06/27/2024, Applicants are requested to submit an updated sequence listing containing all the sequences disclosed in the instant application, as appropriate. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim Interpretation The claim scope has been interpreted as set forth below per the guidance set forth at MPEP § 2111. If Applicant disputes any interpretation, Applicant is invited to unambiguously identify any alleged misinterpretations or specialized definitions in the subsequent response to the instant action. Applicant is advised that a specialized definition should be properly supported and specifically identified (see, e.g., MPEP § 211 l.0l(IV), describing how Applicant may act as their own lexicographer). The instant claims recite “a peptide comprising the amino acid sequence…”. "Comprising" is an open-ended transitional term (see, e.g., MPEP § 2111.03(1)), wherein additional steps or components are not excluded. However, "'[c]omprising' is a term of art used in claim language which means that the named elements are essential" (see, e.g., id.; see also Genentech, Inc. v. Chiron Corp., 112 F.3d 495, 501, 42 USPQ2d 1608, 1613 (Fed. Cir. 1997)). Thus, Examiner in interpreting the claims such that the instant peptide can be comprised in a larger sequence. Therefore, a reference that teaches a peptide or sequence that comprises the instant peptide, would read on the instant claims. Claims 1-10, and 13-15 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Baik et al. (WO2018225961A1 – hereinafter “Baik”). The teaching of the WO2018225961A1 publication are based on the English language translation of the WO2018225961A1 publication obtained by WIPO translate and the citations are based on the English language translation. Regarding claims 1-2, Baik teaches peptides with the sequence Hyp-Gly-Gln-Glu-Gly-Leu-Ala-Gly-Pro-Lys; Hyp-Gly-Gln-Asn-Gly-Leu-Ala-Gly-Pro-Lys (claim 12, 13, 17; Table 1). Examiner notes that the peptide of Baik comprises the instant peptide which comprises Hyp-Gly-Gln, A4 is Glu or Asn, A5 is Gly, A6 is Leu, and A7 is Ala. The disclosures of Baik anticipate the instant claims. Regarding claims 3 and 5, Baik teaches peptides with the sequence Hyp-Gly-Gln-Glu-Gly-Leu-Ala-Gly-Pro-Lys; Hyp-Gly-Gln-Asn-Gly-Leu-Ala-Gly-Pro-Lys (claims 12, 13, 17; Table 1). Examiner notes that the peptide of Baik comprises the instant peptide Hyp-Gly-Gln-Glu-Gly-Leu-Ala and Hyp-Gly-Gln-Asn-Gly-Leu-Ala thus anticipating the claims. Regarding claim 4, Baik teaches pharmaceutical composition comprising the peptide and a suitable carriers or excipients (Page 28, 4th to 6th paragraph). Regarding claims 6, 10, and 15, Baik teaches that the composition comprises the peptide at a concentration of 0.01 μM to 1 μΜ, 30 μΜ to 1 μΜ, 50 μΜ to 0.02 μΜ (Page 28, last two paragraphs). Regarding claim 7, Baik teaches the composition may be administered via intravenous, intraarterial, intraperitoneal, intramuscular, intrasternal, transdermal, nasal or may be carried out via any one route selected from the group consisting of intralateral, inhalation topical, rectal, oral, intraocular and intradermal (Page 29, 1st paragraph). Regarding claim 8, Baik teaches peptides with the sequence Hyp-Gly-Gln-Glu-Gly-Leu-Ala-Gly-Pro-Lys; Hyp-Gly-Gln-Asn-Gly-Leu-Ala-Gly-Pro-Lys (claim 12, 13, 17; Table 1). Examiner notes that the peptide of Baik comprises the instant peptide which comprises Hyp-Gly-Gln, A4 is Glu or Asn, A5 is Gly, A6 is Leu, and A7 is Ala. Examiner notes that the peptide of claim 1 is taught by Baik and that the recitation of “food composition” is being interpreted as the intended use of the composition. Regarding claims 9 and 14, Baik teaches peptides with the sequence Hyp-Gly-Gln-Glu-Gly-Leu-Ala-Gly-Pro-Lys; Hyp-Gly-Gln-Asn-Gly-Leu-Ala-Gly-Pro-Lys (claims 12, 13, 17; Table 1). Examiner notes that the peptide of Baik comprises the instant peptide Hyp-Gly-Gln-Glu-Gly-Leu-Ala and Hyp-Gly-Gln-Asn-Gly-Leu-Ala thus anticipating the claims. Regarding claim 13, Baik teaches peptides with the sequence Hyp-Gly-Gln-Glu-Gly-Leu-Ala-Gly-Pro-Lys; Hyp-Gly-Gln-Asn-Gly-Leu-Ala-Gly-Pro-Lys (claim 12, 13, 17; Table 1). Examiner notes that the peptide of Baik comprises the instant peptide which comprises Hyp-Gly-Gln, A4 is Glu or Asn, A5 is Gly, A6 is Leu, and A7 is Ala. Examiner notes that the peptide of claim 1 is taught by Baik and that the recitation of “food composition” is being interpreted as the intended use of the composition. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 8-12 are rejected under 35 U.S.C. 103 as being unpatentable over Baik et al. (WO2018225961A1 – hereinafter “Baik”) as applied to claim 1 above, and further in view of Yang et al. (US20190111112A1 – hereinafter “Yang”). The teachings of Baik are disclosed above and incorporated herein by reference. Baik does not teach wherein the composition comprising the peptide is a food composition wherein the food composition is a feed or feed additive. However, the instant peptide is known to be included in food compositions as taught by Yang. Yang teaches a collagen peptide that comprises the sequence hydroxy proline-GQDGLAGPK (SEQ ID NO: 1) [0014-0034]. Yang further teaches a health food composition that comprises the peptide [0008, 0010, 0012, 0051, 0062, 0072]. It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the teachings of Baik and prepare a food composition comprising the peptide since Yang teaches the instant peptide in a food composition. One of ordinary skill in the art would be motivated and would have had a reasonable expectation of success in including the instant peptide in a food composition since Yang teaches the same instant peptide as the active ingredient in a food composition. The disclosures render obvious claim 8. Regarding claim 9, Baik teaches peptides with the sequence Hyp-Gly-Gln-Glu-Gly-Leu-Ala-Gly-Pro-Lys; Hyp-Gly-Gln-Asn-Gly-Leu-Ala-Gly-Pro-Lys (claims 1-12; Table 1). Examiner notes that the peptide of Baik comprises the instant peptide Hyp-Gly-Gln-Glu-Gly-Leu-Ala and Hyp-Gly-Gln-Asn-Gly-Leu-Ala. Additionally, Yang teaches a collagen peptide that comprises the sequence hydroxy proline-GQDGLAGPK (SEQ ID NO: 1) [0014-0034] which comprises the instant peptide. Regarding claim 10, Baik teaches that the composition comprises the peptide at a concentration of 0.01 uM to 1 μΜ, 30 μΜ to 1 μΜ, 50 μΜ to 0.02 μΜ (Page 28, last two paragraphs). Regarding claim 11, Yang teaches the health food composition comprising the peptide wherein the health food is a food additive [0078]. It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the teachings of Baik and prepare a food composition comprising the peptide since Yang teaches the instant peptide in a food composition. Regarding claim 12, Yang teaches that the composition may include tablets, pills, powders, granules, capsules [0074]. Yang further teaches that the health food includes beverages, tea, drinks [0080. It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the teachings of Baik and prepare a food composition comprising the peptide since Yang teaches the instant peptide in a food composition. Claims 13-16 are rejected under 35 U.S.C. 103 as being unpatentable over Baik et al. (WO2018225961A1 – hereinafter “Baik”) as applied to claim 1 above, and further in view of Sakai et al. (JP2003137807A – hereinafter “Sakai”). The teaching of the JP2003137807A publication are based on the English language translation of the JP2003137807A publication obtained by WIPO translate and the citations are based on the English language translation. The teachings of Baik are disclosed above and incorporated herein by reference. Baik does not teach wherein the composition is a cosmetic composition such as a paste, cream or gel. However, such short peptides comprising Hyp are known to be included in cosmetic compositions as taught by Sakai. Sakai teaches collagen peptide compositions that comprise Hyp and teach cosmetic compositions comprising the peptides (Abstract; [0020, 0040-0042, 0047]), that the composition can contain a perfume or other additives [0048], that the cosmetic composition may be a milky lotion, a cream, an ointment, a pack, an aerosol, a water-oil two-layer agent, a cosmetic liquid, a gel [0047]. It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the teachings of Baik and include the peptides in a cosmetic composition since such short peptides comprising Hyp are known to be included in cosmetic compositions as taught by Sakai. One of ordinary skill in the art would be motivated and would have had a reasonable expectation of success in including the peptides of Baik in a cosmetic composition since such short peptides comprising Hyp are known to be included in cosmetic compositions as taught by Sakai. The teachings render obvious claim 13. Regarding claim 14, Baik teaches peptides with the sequence Hyp-Gly-Gln-Glu-Gly-Leu-Ala-Gly-Pro-Lys; Hyp-Gly-Gln-Asn-Gly-Leu-Ala-Gly-Pro-Lys (claims 1-12; Table 1). Examiner notes that the peptide of Baik comprises the instant peptide Hyp-Gly-Gln-Glu-Gly-Leu-Ala and Hyp-Gly-Gln-Asn-Gly-Leu-Ala. Regarding claim 15, Baik teaches that the composition comprises the peptide at a concentration of 0.01 uM to 1 μΜ, 30 μΜ to 1 μΜ, 50 μΜ to 0.02 μΜ (Page 28, last two paragraphs). Regarding claim 16, Sakai teaches collagen peptide compositions that comprise Hyp and teach cosmetic compositions comprising the peptides (Abstract; [0020, 0040-0042, 0047]), that the composition can contain a perfume or other additives [0048], that the cosmetic composition may be a milky lotion, a cream, an ointment, a pack, an aerosol, a water-oil two-layer agent, a cosmetic liquid, a gel [0047]. It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the teachings of Baik and include the peptides in a cosmetic composition such as a lotion since such short peptides comprising Hyp are known to be included in cosmetic compositions as taught by Sakai. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1-5, 8-9, 13-14 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-5 of U.S. Patent No. US12428446B2. Although the claims at issue are not identical, they are not patentably distinct from each other because the claims of the patent recite a peptide or a pharmaceutically acceptable salt thereof, wherein the peptide is selected from the group consisting of Hyp-Gly-Gln-Glu-Leu-Leu-Ala (SEQ ID NO.: 77), Hyp-Gly-Gln-Glu-Val-Leu-Ala (SEQ ID NO.: 78), and Hyp-Gly-Gln-Glu-Aib-Leu-Ala (SEQ ID NO.: 83) (claim 1). The instant claims recite a peptide comprising the amino acid sequence Hyp-Gly-Gln-A4-A5-A6-A7, or a pharmaceutically acceptable salt thereof, wherein: A4 is Ala, Asn, Asp, isopropyl ester-substituted Asp, D-Asp, Asu, or Glu; A5 is Aib, Ala, Gly, phenyl-Gly, Leu, tert-Leu, or Val; A6 is Leu, D-Leu, Pro, or Val; and A7 is Ala, D-Ala, or isopropyl ester-substituted Ala (claim 1), wherein the peptides include Hyp-Gly-Gln-Glu-Leu-Leu-Ala, Hyp-Gly-Gln-Glu-Val-Leu-Ala, and Hyp-Gly-Gln-Glu-Aib-Leu-Ala (claims 3, 5, 9). The claims of the patent anticipate the instant claims. Regarding claims 1-5, the claims of the patent recite a peptide or a pharmaceutically acceptable salt thereof, wherein the peptide is selected from the group consisting of Hyp-Gly-Gln-Glu-Leu-Leu-Ala (SEQ ID NO.: 77), Hyp-Gly-Gln-Glu-Val-Leu-Ala (SEQ ID NO.: 78), and Hyp-Gly-Gln-Glu-Aib-Leu-Ala (SEQ ID NO.: 83) (claim 1), and further recites a pharmaceutical composition comprising the peptide (claim 3). Regarding claims 8-9, the claims of the patent recite a peptide or a pharmaceutically acceptable salt thereof, wherein the peptide is selected from the group consisting of Hyp-Gly-Gln-Glu-Leu-Leu-Ala (SEQ ID NO.: 77), Hyp-Gly-Gln-Glu-Val-Leu-Ala (SEQ ID NO.: 78), and Hyp-Gly-Gln-Glu-Aib-Leu-Ala (SEQ ID NO.: 83) (claim 1), and further recites a food composition comprising the peptide (claim 4). Regarding claims 13-14, the claims of the patent recite a peptide or a pharmaceutically acceptable salt thereof, wherein the peptide is selected from the group consisting of Hyp-Gly-Gln-Glu-Leu-Leu-Ala (SEQ ID NO.: 77), Hyp-Gly-Gln-Glu-Val-Leu-Ala (SEQ ID NO.: 78), and Hyp-Gly-Gln-Glu-Aib-Leu-Ala (SEQ ID NO.: 83) (claim 1), and further recites a cosmetic composition comprising the peptide (claim 5). Claims 1-16 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-5 of U.S. Patent No. US12428446B2 in view of Baik et al. (WO2018225961A1 – hereinafter “Baik”), Yang et al. (US20190111112A1 – hereinafter “Yang”) and Sakai et al. (JP2003137807A – hereinafter “Sakai”). Although the claims at issue are not identical, they are not patentably distinct from each other because the claims of the patent recite a peptide or a pharmaceutically acceptable salt thereof, wherein the peptide is selected from the group consisting of Hyp-Gly-Gln-Glu-Leu-Leu-Ala (SEQ ID NO.: 77), Hyp-Gly-Gln-Glu-Val-Leu-Ala (SEQ ID NO.: 78), and Hyp-Gly-Gln-Glu-Aib-Leu-Ala (SEQ ID NO.: 83) (claim 1). The instant claims recite a peptide comprising the amino acid sequence Hyp-Gly-Gln-A4-A5-A6-A7, or a pharmaceutically acceptable salt thereof, wherein: A4 is Ala, Asn, Asp, isopropyl ester-substituted Asp, D-Asp, Asu, or Glu; A5 is Aib, Ala, Gly, phenyl-Gly, Leu, tert-Leu, or Val; A6 is Leu, D-Leu, Pro, or Val; and A7 is Ala, D-Ala, or isopropyl ester-substituted Ala (claim 1), wherein the peptides include Hyp-Gly-Gln-Glu-Leu-Leu-Ala, Hyp-Gly-Gln-Glu-Val-Leu-Ala, and Hyp-Gly-Gln-Glu-Aib-Leu-Ala (claims 3, 5, 9). The difference between the claims of the patent and the instant claims is that the claims of the patent do not recite the concentration of the peptide and the type of composition as recited in claims 10-12 and 15-16. However, the peptides are known to be included in the composition in the recited concentrations as taught by Baik et al. Baik teaches peptides with the sequence Hyp-Gly-Gln-Glu-Gly-Leu-Ala-Gly-Pro-Lys; Hyp-Gly-Gln-Asn-Gly-Leu-Ala-Gly-Pro-Lys (claims 1-12; Table 1). Examiner notes that the peptide of Baik comprises the instant peptide which comprises Hyp-Gly-Gln, A4 is Glu or Asn, A5 is Gly, A6 is Leu, and A7 is Ala. Baik teaches pharmaceutical composition comprising the peptide and a suitable carriers or excipients (Page 28, 4th to 6th paragraph). Baik teaches that the composition comprises the peptide at a concentration of 0.01 uM to 1 μΜ, 30 μΜ to 1 μΜ, 50 μΜ to 0.02 μΜ (Page 28, last two paragraphs). Baik teaches the composition may be administered via intravenous, intraarterial, intraperitoneal, intramuscular, intrasternal, transdermal, nasal or may be carried out via any one route selected from the group consisting of intralateral, inhalation topical, rectal, oral, intraocular and intradermal (Page 29, 1st paragraph). Yang teaches a collagen peptide that comprises the sequence hydroxy proline-GQDGLAGPK (SEQ ID NO: 1) [0014-0034]. Yang further teaches a health food composition that comprises the peptide [0008, 0010, 0012, 0051, 0062, 0072]. Yang teaches the health food composition comprising the peptide wherein the health food is a food additive [0078]. Yang teaches that the composition may include tablets, pills, powders, granules, capsules [0074]. Yang further teaches that the health food includes beverages, tea, drinks [0080]. Sakai teaches collagen peptide compositions that comprise Hyp and teach cosmetic compositions comprising the peptides (Abstract; [0020, 0040-0042, 0047]), that the composition can contain a perfume or other additives [0048], that the cosmetic composition may be a milky lotion, a cream, an ointment, a pack, an aerosol, a water-oil two-layer agent, a cosmetic liquid, a gel [0047]. It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the claims of the patent with the teachings of Baik, Yang and Sakai and include the peptides in the recited concentrations and in the composition forms as taught by Yang and Sakai since the references teach the instant peptides in food and cosmetic composition and in the recited concentrations. One of ordinary skill in the art would be motivated and would have had a reasonable expectation of success in including the peptides in the concentrations as taught by Baik since such short peptides comprising Hyp are known to be included in food and cosmetic compositions in the recited concentrations. The claims of the patent render obvious the instant claims. Regarding claims 1-5, the claims of the patent recite a peptide or a pharmaceutically acceptable salt thereof, wherein the peptide is selected from the group consisting of Hyp-Gly-Gln-Glu-Leu-Leu-Ala (SEQ ID NO.: 77), Hyp-Gly-Gln-Glu-Val-Leu-Ala (SEQ ID NO.: 78), and Hyp-Gly-Gln-Glu-Aib-Leu-Ala (SEQ ID NO.: 83) (claim 1), and further recites a pharmaceutical composition comprising the peptide (claim 3). Regarding claims 6, 10, and 15, Baik teaches that the composition comprises the peptide at a concentration of 0.01 uM to 1 μΜ, 30 μΜ to 1 μΜ, 50 μΜ to 0.02 μΜ (Page 28, last two paragraphs). It would have been obvious to one of ordinary skill in the art to modify the claims of the patent and include the peptides in the recited concentrations as taught by Baik. Regarding claim 7, Baik teaches the composition may be administered via intravenous, intraarterial, intraperitoneal, intramuscular, intrasternal, transdermal, nasal or may be carried out via any one route selected from the group consisting of intralateral, inhalation topical, rectal, oral, intraocular and intradermal (Page 29, 1st paragraph). It would have been obvious to one of ordinary skill in the art to modify the claims of the patent and have the composition for oral administration as taught by Baik. Regarding claims 8-9, the claims of the patent recite a peptide or a pharmaceutically acceptable salt thereof, wherein the peptide is selected from the group consisting of Hyp-Gly-Gln-Glu-Leu-Leu-Ala (SEQ ID NO.: 77), Hyp-Gly-Gln-Glu-Val-Leu-Ala (SEQ ID NO.: 78), and Hyp-Gly-Gln-Glu-Aib-Leu-Ala (SEQ ID NO.: 83) (claim 1), and further recites a food composition comprising the peptide (claim 4). Regarding claims 11-12, Yang teaches the health food composition comprising the peptide wherein the health food is a food additive [0078]. Yang further teaches that the composition may include tablets, pills, powders, granules, capsules [0074]. Yang further teaches that the health food includes beverages, tea, drinks [0080]. It would have been obvious to one of ordinary skill in the art to modify the claims of the patent and formulate the food composition as a feed additive and in form of a beverage as taught by Yang. Regarding claims 13-14, the claims of the patent recite a peptide or a pharmaceutically acceptable salt thereof, wherein the peptide is selected from the group consisting of Hyp-Gly-Gln-Glu-Leu-Leu-Ala (SEQ ID NO.: 77), Hyp-Gly-Gln-Glu-Val-Leu-Ala (SEQ ID NO.: 78), and Hyp-Gly-Gln-Glu-Aib-Leu-Ala (SEQ ID NO.: 83) (claim 1), and further recites a cosmetic composition comprising the peptide (claim 5). Regarding claim 16, Sakai teaches collagen peptide compositions that comprise Hyp and teach cosmetic compositions comprising the peptides (Abstract; [0020, 0040-0042, 0047]), that the composition can contain a perfume or other additives [0048], that the cosmetic composition may be a milky lotion, a cream, an ointment, a pack, an aerosol, a water-oil two-layer agent, a cosmetic liquid, a gel [0047]. It would have been obvious to one of ordinary skill in the art to modify the claims of the patent and include the peptides in a cosmetic composition such as a lotion since such short peptides comprising Hyp are known to be included in cosmetic compositions as taught by Sakai. Conclusion No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Mercy H. Sabila whose telephone number is (571)272-2562. The examiner can normally be reached Monday - Friday 5:00 am - 3:00 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Lianko G. Garyu can be reached at (571)270-7367. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MERCY H SABILA/Examiner, Art Unit 1654 /LIANKO G GARYU/ Supervisory Patent Examiner, Art Unit 1654
Read full office action

Prosecution Timeline

Jun 27, 2024
Application Filed
Oct 20, 2026
Non-Final Rejection mailed — §102, §103, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12788009
INSECT NEUROPEPTIDES 2
1y 9m to grant Granted Nov 10, 2026
Patent 12697366
THERMOGENIC COMPOSITIONS AND METHODS
5y 0m to grant Granted Aug 04, 2026
Patent 12662492
SITE-SPECIFIC ANTIBODY CONJUGATION AND ANTIBODY-DRUG CONJUGATE AS SPECIFIC EMBODIMENT THEREOF
5y 9m to grant Granted Jun 23, 2026
Patent 12629410
MULTI-ANTIGENIC PEPTIDE MIMICS OF GONOCOCCAL LIPO-OLIGOSACCHARIDE (LOS) EPITOPES
4y 2m to grant Granted May 19, 2026
Patent 12617831
PEPTIDE TARGETING GIP AND GLP-2 RECEPTORS FOR TREATING BONE DISORDERS
4y 8m to grant Granted May 05, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
57%
Grant Probability
99%
With Interview (+46.4%)
Low
PTA Risk
Based on 278 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month